PA
COGT icon

Parallel Advisors’s Cogent Biosciences COGT Stock Holding History

Parallel Advisors’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.4K Buy
+1,024
New +$37.8K ﹤0.01% 2131
2022
Q4 		– Sell
-8
Closed – – 3379
2022
Q3 		$0 Buy
+8
New +$110 ﹤0.01% 3188

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Parallel Advisors's COGT Position: Q1 2026 in Review

Parallel Advisors opened a new position in Cogent Biosciences (COGT) in Q1 2026: 1,024 shares worth $39.4K. The stake represents ﹤0.01% of the portfolio and ranks #2131 among its holdings. This is a return to the name: Parallel Advisors previously reported a position in COGT as recently as Q3 2022.

Parallel Advisors first reported a position in COGT in Q3 2022 and has held it in 2 quarters since. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Parallel Advisors held 1,024 shares of Cogent Biosciences worth $39.4K as of Q1 2026.
  • Cogent Biosciences was a new Parallel Advisors position in Q1 2026.
  • Cogent Biosciences made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #2131 holding.
  • Parallel Advisors first reported a position in Cogent Biosciences in Q3 2022 and has held it in 2 quarters since.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.